Clinical Trial Update: Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and clinical effectiveness of the oral probiotic MIYA-BM to prevent recurrent Clostridioides difficile infection has been wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• MIYA-BM

Snippet

Sponsor: Osel, Inc. | Conditions: Clostridium Difficile Infection | Phase 2 | Status: WITHDRAWN